Quote:

---

The final results from that study have now also demonstrated that leronlimab (both high and low dose) was significantly better than Resmetirom at reversal of fat deposition (steatosis) in the liver. These exciting findings have been submitted as a late breaker abstract to the MASH TAG conference and, if accepted, will be presented at the meeting in January.

---

It's at The Chateaux Deer Valley in Park City UT.

I volunteer to go and take notes, when not skiiing, drinking or hob-nobbing with the bougies.

I'll set up a gofundme right now.